Show simple item record

dc.contributor.authorGillison, ML
dc.contributor.authorBlumenschein, G
dc.contributor.authorFayette, J
dc.contributor.authorGuigay, J
dc.contributor.authorColevas, AD
dc.contributor.authorLicitra, L
dc.contributor.authorHarrington, KJ
dc.contributor.authorKasper, S
dc.contributor.authorVokes, EE
dc.contributor.authorEven, C
dc.contributor.authorWorden, F
dc.contributor.authorSaba, NF
dc.contributor.authorDocampo, LCI
dc.contributor.authorHaddad, R
dc.contributor.authorRordorf, T
dc.contributor.authorKiyota, N
dc.contributor.authorTahara, M
dc.contributor.authorJayaprakash, V
dc.contributor.authorWei, L
dc.contributor.authorFerris, RL
dc.date.accessioned2022-04-06T10:11:35Z
dc.date.available2022-04-06T10:11:35Z
dc.date.issued2022-03-04
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000764264500021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9en_US
dc.identifier.citationONCOLOGIST, 2022, 27 (2), pp. E194 - E198 (5)en
dc.identifier.issn1083-7159
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5073
dc.identifier.eissn1549-490Xen_US
dc.identifier.eissn1549-490X
dc.identifier.doi10.1093/oncolo/oyab036en_US
dc.identifier.doi10.1093/oncolo/oyab036
dc.format.extentE194 - E198 (5)en_US
dc.languageEnglishen_US
dc.language.isoengen
dc.publisherOXFORD UNIV PRESSen
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0en
dc.subjectScience & Technologyen_US
dc.subjectLife Sciences & Biomedicineen_US
dc.subjectOncologyen_US
dc.subjectclinical trialen_US
dc.subjectsquamous cell carcinoma of head and necken_US
dc.subjectnivolumaben_US
dc.subjectimmunotherapyen_US
dc.subjectSQUAMOUS-CELL CARCINOMAen_US
dc.subjectINVESTIGATORS CHOICEen_US
dc.subjectOPEN-LABELen_US
dc.subjectCETUXIMABen_US
dc.subjectCHEMOTHERAPYen_US
dc.subjectPLATINUMen_US
dc.titleLong-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141en
dc.typeJournal Article
dcterms.dateAccepted2021-11-30
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1093/oncolo/oyab036en
rioxxterms.licenseref.startdate2022-03-04
dc.relation.isPartOfONCOLOGISTen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume27en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapy
dc.contributor.icrauthorHarrington, Kevinen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0